Transgender Healthcare in the US: A Medical Guide to Gender-Affirming Care

Gender-affirming care refers to the range of social, psychological, medical, and surgical interventions that support a person's gender identity when it differs from their sex assigned at birth. For transgender adults, the medical components most commonly include hormone therapy and, for those who choose it, gender-affirming surgeries. The evidence base supporting these interventions is substantial: systematic reviews and decades of longitudinal data consistently demonstrate that access to gender-affirming care is associated with significant reductions in depression, anxiety, suicidality, and psychological distress in transgender individuals, and with improvements in overall quality of life and functional status. Every major US and international medical organization — including the American Medical Association, American Academy of Pediatrics, American Psychological Association, American College of Physicians, ACOG, and WPATH (World Professional Association for Transgender Health) — endorses gender-affirming care as medically necessary treatment for gender dysphoria.

What Gender-Affirming Care Includes

Gender-affirming care is not a single treatment — it is a spectrum of interventions chosen by the individual in partnership with their healthcare team. The spectrum includes:

• Social transition: Using one's affirmed name and pronouns, changing dress or presentation. Requires no medical intervention.
• Mental health support: Therapy with an affirming provider, addressing gender dysphoria, minority stress, family dynamics, and the practical challenges of navigating a world that does not always accommodate trans identities. Mental health care is not a prerequisite for hormone therapy under current informed consent models but is highly valuable.
• Hormone therapy: Medical treatment that aligns physical characteristics more closely with gender identity. The most common and widely sought medical intervention.
• Gender-affirming surgeries: A range of procedures that modify primary and secondary sex characteristics. Not all trans people pursue surgery, and surgery is not required for any level of social or medical gender affirmation.
• Preventive and ongoing care: Routine health maintenance tailored to the individual's anatomy and hormone status, regardless of identity.

Hormone Therapy for Transgender Women (Feminizing Hormone Therapy)

Feminizing hormone therapy for trans women (transfeminine individuals) typically involves two pharmacological components: estrogen to promote feminization, and an androgen blocker (anti-androgen) to suppress testosterone and its masculinizing effects.

Estrogen

Estradiol is the primary feminizing hormone. It is available in several forms in the United States:

• Estradiol patches (transdermal): Applied to skin 1–2 times weekly. Associated with lower venous thromboembolism (VTE/blood clot) risk than oral estradiol and is often preferred in patients with cardiovascular or clotting risk factors.
• Estradiol gel or spray (transdermal): Applied daily. Lower clot risk profile similar to patches.
• Oral estradiol: Convenient but first-pass hepatic metabolism increases clot risk relative to transdermal. Avoid in smokers and those with VTE history.
• Estradiol injections: Estradiol valerate or cypionate, typically weekly or biweekly. Produces higher peak levels and more variable trough levels; preferred by many patients for its potency.

Target estradiol levels on feminizing therapy are typically 100–200 pg/mL (similar to the range in cisgender women), with testosterone suppressed below 50 ng/dL.

Anti-Androgens

• Spironolactone: The most commonly prescribed anti-androgen in the US. It blocks androgen receptors and reduces adrenal androgen production. Starting dose is typically 50–100 mg daily, titrated to 100–200 mg. Requires potassium monitoring, particularly in patients on medications that also raise potassium.
• Bicalutamide: A competitive androgen receptor blocker with a favorable side effect profile; increasingly used as an alternative to spironolactone.
• GnRH agonists (leuprolide/Lupron): Highly effective testosterone suppression by blocking the pituitary signaling to the testes; expensive without insurance coverage.
• Progesterone: Often requested by transfeminine patients; evidence for feminizing benefit is limited but some providers use it for breast development or mood benefits. Bioidentical micronized progesterone (Prometrium) preferred over synthetic progestins.

Physical Effects: Timeline

Effects of feminizing hormone therapy develop gradually over months to years:

• 1–3 months: Decreased libido, decreased spontaneous erections, some softening of skin texture.
• 3–6 months: Breast development begins (typically with tenderness), redistribution of body fat (hips, thighs, buttocks), decreased muscle mass and strength beginning.
• 6–12 months: Continued breast growth, further fat redistribution, reduced body hair growth (slower and finer), softening of facial features.
• 1–3 years: Maximum breast development (typically 1–2 cup sizes smaller than maternal relatives), full fat redistribution effect, significant body hair reduction. Scalp hair regrowth in those with prior DHT-driven recession.

Effects that do not change with estrogen: voice pitch (without voice therapy or surgery), bone structure, height, hand/foot size, or facial bone structure (without surgical intervention).

Monitoring

Clinical monitoring at 3 months initially, then every 6–12 months once stable, includes: estradiol level, testosterone level, complete blood count (estrogen increases red blood cell production modestly), potassium (spironolactone), liver function, and blood pressure. Bone density monitoring is recommended for patients who have been on hormone therapy for more than 5 years. Routine breast cancer screening considerations apply given breast tissue development.

Hormone Therapy for Transgender Men (Masculinizing Hormone Therapy)

Masculinizing hormone therapy for trans men (transmasculine individuals) involves testosterone, which produces virilizing effects.

Testosterone

Testosterone is available as:

• Injectable testosterone (cypionate or enanthate): Intramuscular or subcutaneous injection every 1–2 weeks. Most cost-effective and widely used option. Peaks 24–48 hours after injection with trough before the next dose; weekly injection produces more stable levels than biweekly.
• Testosterone gel (AndroGel, Testim, Axiron): Applied daily to skin. Produces more stable levels than injections but carries risk of transference to others via skin contact.
• Testosterone patches: Applied daily; skin irritation is a common issue.

Target testosterone levels on masculinizing therapy are generally 400–700 ng/dL (mid-normal cisgender male range).

Physical Effects: Timeline

• 1–3 months: Increased clitoral size (clitoromegaly), increased libido, skin becoming oilier, possible early acne, vaginal atrophy beginning (can cause discomfort; topical estrogen or moisturizers are appropriate).
• 3–6 months: Menstruation typically stops or becomes irregular and lighter. Voice begins to deepen — this is typically irreversible.
• 6–12 months: Significant voice deepening (often perceived as the most important early change by many patients), increase in body and facial hair growth, body fat redistribution toward abdominal/truncal pattern, increased muscle mass with exercise.
• 1–3 years: Facial hair continues to develop for up to 5 years, reaching family-genetic pattern. Scalp hair loss may occur in those with genetic predisposition to androgenetic alopecia. Near-maximal virilization typically achieved by years 2–5.

Effects that do not reverse once established: voice deepening, clitoral growth, body and facial hair growth, and scalp hair loss.

Monitoring

Monitoring at 3 months initially then every 6–12 months includes: testosterone level (trough for injectables), hematocrit and hemoglobin (testosterone stimulates red blood cell production; polycythemia is a risk at high levels or with high doses), lipid panel (testosterone lowers HDL and raises LDL), liver function. Cervical cancer screening (Pap smear) recommendations apply to trans men with a cervix, though pelvic exams can be distressing and should be approached with sensitivity and appropriate positioning. Uterine and ovarian cancer risks persist as long as these organs remain in situ.

Surgical Options Overview

Gender-affirming surgeries are diverse and highly individualized. Not all trans people pursue surgery; the decision is personal and medical, not a measure of trans identity.

For Transfeminine Individuals

• Orchiectomy: Removal of the testes; eliminates testosterone production, simplifying and reducing hormone management, and providing genital dysphoria relief. A less complex procedure than full vaginoplasty.
• Vaginoplasty (penile inversion or sigmoid colon techniques): Construction of a vaginal canal and external genitalia. Requires dilation postoperatively for 6–12 months to maintain depth and width. Achieves functional and anatomical outcomes that most patients rate as satisfactory to excellent in long-term studies.
• Breast augmentation: Many trans women pursue augmentation if estrogen-induced breast development has not achieved their desired size. Performed using the same techniques as augmentation in cisgender women.
• Facial feminization surgery (FFS): A range of facial bone and soft tissue procedures (brow ridge reduction, rhinoplasty, tracheal shave, jaw and chin contouring) that address facial features causing gender dysphoria. Many trans women report FFS as profoundly impactful on gender dysphoria and quality of life.

For Transmasculine Individuals

• Chest masculinization surgery (top surgery): The most commonly pursued surgical intervention in trans men — bilateral mastectomy with male chest contouring and nipple repositioning. High satisfaction rates; studies show near-universal improvement in chest dysphoria postoperatively.
• Hysterectomy and oophorectomy: Removal of the uterus and ovaries. Eliminates menstruation, reduces pelvic dysphoria, simplifies long-term hormone management, and removes the ongoing risk of uterine cancer.
• Phalloplasty or metoidioplasty: Complex lower-surgery options. Metoidioplasty (releasing and freeing the testosterone-enlarged clitoris) is a less complex procedure with a shorter recovery. Phalloplasty (construction of a phallus using donor tissue, typically from the forearm or thigh) is a complex multi-stage procedure with the potential for erectile implant and standing urination; complication rates are significant and should be discussed in detail with an experienced surgeon.

The Mental Health Benefits of Affirming Care: What the Research Shows

The evidence for mental health benefits of gender-affirming care is consistent across study designs, populations, and countries. A 2020 systematic review in The Lancet Diabetes & Endocrinology found that gender-affirming hormone therapy was associated with significant reductions in depression, anxiety, and psychological distress, and significant improvements in quality of life. A 2022 study in JAMA Network Open found that access to gender-affirming puberty blockers and hormone therapy in adolescence was associated with substantially lower odds of suicidality in adulthood. Studies in trans adults consistently show that surgical intervention in those who desired it was associated with improved mental health outcomes.

Trans individuals who lack access to affirming care, or who live in environments with high levels of minority stress and discrimination, have dramatically higher rates of depression (approximately 40–50%), anxiety (approximately 40%), and suicidality (lifetime attempts approximately 40%) compared to the general population. These rates are substantially reduced in supportive environments with access to care — underscoring that mental health disparities in trans populations are driven primarily by discrimination, rejection, and denied care, not by trans identity itself.

Insurance, Access, and the Legal Landscape

Insurance coverage for gender-affirming care has expanded substantially since the ACA prohibited sex-based discrimination in health coverage. Many commercial plans cover hormone therapy and some surgeries when medically documented. Medicaid coverage for gender-affirming care exists in 30+ states as of 2025. Medicare covers hormone therapy and medically necessary surgeries for gender dysphoria.

Access remains highly variable by geography. Provider shortages — particularly for gender-affirming surgeons — are significant in many regions. Informed consent models (where hormone therapy can be initiated by any qualified clinician after a patient provides informed consent, without requiring letters from mental health providers) have expanded access and are now standard practice at most major healthcare systems and Planned Parenthood affiliates.

The federal Affordable Care Act's Section 1557 prohibits sex discrimination in covered healthcare programs, which courts have interpreted to include gender identity discrimination. Patients who experience discrimination in healthcare have the right to file a complaint with the Office for Civil Rights (OCR) at the Department of Health and Human Services (HHS).

Finding Affirming Providers

Finding a knowledgeable, affirming provider is one of the most cited barriers to care in trans communities. Resources for finding affirming providers include the GLMA (Health Professionals Advancing LGBTQ+ Equality) provider directory, Folx Health, Plume (online trans healthcare), and state LGBTQ health center directories. Planned Parenthood affiliates in many states provide hormone therapy under informed consent models. Trans Lifeline (877-565-8860) and The Trevor Project (1-866-488-7386) provide crisis support and can assist with resource navigation.

Ongoing Preventive Healthcare for Trans Adults

Trans individuals need the same preventive healthcare as anyone else, plus monitoring specific to their hormonal and anatomical status. Trans women need breast cancer screening per relevant guidelines given breast tissue development. Trans men with a cervix need Pap smears per cervical cancer screening guidelines (annual until 3 years of normal results, then every 3 years or 5 years with cotesting). Both trans men and trans women on long-term hormone therapy need bone density monitoring. Cardiovascular risk assessment is important given the metabolic effects of hormone therapy and the higher rates of cardiovascular risk factors in this population. Routine STI, HIV, and mental health screening should be integrated into all care encounters.

When to See a Doctor

If you are a transgender or nonbinary person seeking hormone therapy, surgical consultation, or any aspect of gender-affirming care, a knowledgeable affirming physician can initiate evaluation and, under informed consent models, prescribe hormone therapy directly. Telehealth has substantially expanded access to gender-affirming care, making it available to people in areas without local providers. JourneyDoctors connects you with trained specialists from $19. Start a consultation today — no waiting room, no referral needed.

This article is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional for diagnosis and treatment.

Frequently Asked Questions

Do I need a therapist's letter to get hormone therapy?

Under the informed consent model, which has become standard at most progressive healthcare centers and telehealth providers in the US, no. You can initiate hormone therapy after a conversation with a knowledgeable clinician in which your goals, health history, risks, and expectations are reviewed and you provide informed consent. Letters from mental health providers were historically required under older gatekeeping models but are no longer necessary under informed consent, and this shift is endorsed by WPATH's Standards of Care v8. Mental health support remains highly valuable and is encouraged, but it is not a prerequisite.

Is hormone therapy permanent?

Some effects of hormone therapy are reversible upon stopping; others are not. For feminizing therapy: breast development is only partially reversible, fat redistribution partially reverses, but skin changes and reduced body hair are largely maintained. For masculinizing therapy: voice deepening, clitoral growth, and body hair growth are permanent. Given the permanence of some effects, informed consent discussions cover this explicitly. Many trans people elect to continue hormone therapy indefinitely because the benefits to quality of life, dysphoria reduction, and well-being substantially outweigh the risks.

Can transgender women get pregnant?

Transgender women who have not undergone orchiectomy and have not been on estrogen therapy long enough to cause permanent spermatogenic suppression may still produce sperm. Fertility preservation (sperm banking) before initiating hormone therapy is recommended for those who want to preserve the option of biological parenthood. Trans women cannot gestate a pregnancy; uterus transplantation in trans women is currently experimental and not clinically available in the US.

Can transgender men get pregnant?

Yes. Trans men who retain a uterus and ovaries can become pregnant, even while on testosterone therapy — testosterone is not a reliable contraceptive. Trans men who wish to avoid pregnancy should use contraception. If pregnancy is desired, testosterone is discontinued (usually several months before attempting conception) and fertility may be preserved or restored once testosterone is stopped. Pregnancy in trans men is medically manageable, though it requires sensitive and knowledgeable obstetric care.

Does gender-affirming care affect cardiovascular health?

Hormone therapy has cardiovascular effects that require monitoring and risk management. Oral estradiol is associated with increased VTE risk; transdermal estradiol has substantially lower clot risk. High-dose estrogen and spironolactone combinations require blood pressure and potassium monitoring. Testosterone therapy lowers HDL cholesterol, raises hematocrit, and requires cardiovascular risk monitoring — particularly in trans men over 40 or those with existing cardiovascular risk factors. These risks are manageable with appropriate monitoring and are generally outweighed by the benefits of hormone therapy in individuals with significant gender dysphoria. Smoking significantly amplifies estrogen-related clot risk and cessation is strongly recommended.